Marco Marino

Dr. Marco Marino

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
BFBarbara Frossi
Barbara Frossi
CTClaudio Tripodo
Claudio Tripodo
CGCarla Guarnotta
Carla Guarnotta
ACAntonio Carroccio
Antonio Carroccio
MCMarco De Carli
Marco De Carli
CPCarlo Pucillo
Carlo Pucillo

9 November 2011 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
SPStefano Passalacqua
Stefano Passalacqua
PFPietro Manuel Ferraro
Pietro Manuel Ferraro
GBGiampaolo Bresci
Giampaolo Bresci
VDValeria D'OVidio
Valeria D'OVidio
MAMarco Astegiano
Marco Astegiano
MSMichele Silla
Michele Silla

15 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DSDario Sorrentino
Dario Sorrentino
MMMarco Marino
Marco Marino
TDThemistocles Dassopoulos
Themistocles Dassopoulos
DZDimitra Zarifi
Dimitra Zarifi
TBTiziana Del Bianco
Tiziana Del Bianco
In patients with postoperative recurrence of Crohn’s disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg). However, in theory low-dose infliximab treated patients could develop subtherapeutic trough levels, infiximab antibodies, and might loose response to therapy. To verify this hypothesis infliximab pharmacokinetics and clinical/endoscopic response were checked in a group of patients treated in the long term with low infliximab doses. Infliximab antibodies, infliximab levels, highly-sensitive CRP and fecal calprotectin were measured during the 8-week interval in 5 consecutive patients in clinical (Crohn’s Disease Activity Index < 150) and endoscopic (Rutgeerts scores 0–1) remission after one year of therapy with infliximab 3 mg/Kg. For comparison with reported standards, infliximab pharmacokinetics and inflammatory parameters were also tested in 6 Crohn’s disease patients who did not undergo surgery and who were in clinical remission while on infliximab 5 mg/Kg. Patients on low infliximab dose also underwent colonoscopy after 18 additional months of therapy. Highly sensitive CRP and fecal calprotectin increased in all patients during the 8-week interval. Infliximab trough levels were lower in patients treated with the low dose compared to controls (mean±SE: 2.0±0.3 vs 4.75±0.83 μg/mL respectively p<0.05). Infliximab antibodies were present in two of the subjects treated with low infliximab dose and in none of the controls. However, in low dose-treated patients after 18 additional months of therapy endoscopy continued to show mucosal remission and none of them developed clinical recurrence or side effects. Patients treated with low infliximab doses had lower trough levels compared to patients treated with 5 mg/Kg and some developed antibodies to infliximab. However, low infliximab doses sustained clinical and endoscopic remission for a total of 30 months of treatment.

12 November 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RDRossana Domenis
Rossana Domenis
MMMarco Marino
Marco Marino
ACAdriana Cifu'
Adriana Cifu'
GSGiulia Scardino
Giulia Scardino
FCFrancesco Curcio
Francesco Curcio
MFMartina Fabris
Martina Fabris
Vedolizumab (VDZ) is a therapeutic monoclonal antibody approved for the treatment of inflammatory bowel diseases (IBD). VDZ selectively binds to the α4β7 integrin and blocks trafficking of a specific subset of gastrointestinal-homing T-lymphocytes to inflamed tissue. Although VDZ has shown promising results in numerous clinical studies a subgroup of patients do not respond adequately. Mechanistic insights and prognostic biomarkers able to predict which patients might benefit from VDZ therapy are currently lacking. Circulating exosomes were isolated from serum of blood donors and VDZ-treated patients by polymer-based precipitation. The surface expression of α4β7 integrin was evaluated by flow cytometry and the levels of exosome-bound VDZ were investigated by Promonitor-VDZ ELISA kit. The capacity of exosomes to interfere with the adhesion of VDZ-treated CD4+ T cells was assessed by adhesion assay. In this study, we showed that serum exosomes isolated from both blood donor and ulcerative colitis patients express on their surface the VDZ target α4β7 integrin. We observed an increased exosomal sequestration of VDZ in anti-TNF exposed patients compared to anti- TNFα naïve patients, according to a greater expression of α4β7 integrin on vesicles surface. Circulating exosomes could compete for VDZ binding with CD4+ T cells since we found that the amount of VDZ bound to T cells was impaired in the presence of exosomes. In addition, we demonstrated that exosomes bind VDZ, which consequently becomes unable to block MadCAM-1-mediated adhesion of lymphocytes. Circulating exosomes might contribute to drug sequestration, possibly affecting the therapeutic efficacy of VDZ in IBD patients. Our data suggest that previous biologic therapy may have altered the sequestration capacity of circulating exosomes, thus reducing the efficacy of VDZ in patients who failed anti-TNF agents.

1 July 2018 in Pancreas
Verified
Journal Article
Closed access
NPNikola Panic
Nikola Panic
FMFederico Macchini
Federico Macchini
SSSonia Solito
Sonia Solito
SBStefania Boccia
Stefania Boccia
ELEmanuele Leoncini
Emanuele Leoncini
MBMilutin Bulajic
Milutin Bulajic
Objectives We conducted a study in order to assess the prevalence of extrapancreatic malignancies (EPMs) in a cohort of patients with intraductal papillary mucinous neoplasms (IPMNs) from northeastern Italy. Methods A study was conducted in hospital Santa Maria della Misericordia, Udine, Italy. Hospital records were screened in order to identify newly diagnosed IPMN cases in the period from January 1, 2009, to December 31, 2015. We searched for EPMs diagnosed previous to, synchronous to, or after the IPMN. The ratio of the observed (O) number of patients with EPMs to the expected (E) was calculated. Results We identified 72 EPMs in 63 (31.8%) of 198 patients included. Among them, 51 (70.8%) were diagnosed previous to, 17 (23.6%) synchronous to, and 4 (5.6%) after the IPMN. Most frequently diagnosed were colorectal (12 patients [6.1%]), breast (8 patients [6.8%, in females]), renal cell (8 patients [4.0%]), and prostate cancer (7 patients [8.6%, in males]). The O/E ratios for EPMs were significantly increased for cancer in general (3.66; 95% confidence interval [CI], 2.39-5.37), renal cell (9.62; 95% CI, 1.98-28.10), prostate (4.91; 95% CI, 1.59-11.45), and breast cancer (3.16; 95% CI, 1.03-7.37). Conclusions We report an increased risk of EPMs in patients with IPMN, especially for renal cell, prostate, colorectal, and breast cancer.

1 February 2015 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
GFGiacomo Faleschini
Giacomo Faleschini
SPSalvatore F. Vadalà di Prampero
Salvatore F. Vadalà di Prampero
MBMilutin Bulajic
Milutin Bulajic
UBUmberto Baccarani
Umberto Baccarani
PTPierluigi Toniutto
Pierluigi Toniutto
MZMaurizio Zilli
Maurizio Zilli
Background and aims The most common complications after liver transplantation nowadays affect the biliary tract. We carried out a retrospective study to identify predictors of endoscopic treatment outcome in the management of post-transplantation biliary complications. Methods Data from all patients with post-transplantation biliary complications subjected to endoscopic treatment at the University of Udine between 2000 and 2012 were extracted. To identify predictors of endoscopic treatment outcome, a logistic regression analysis was carried out. Cox modeling was used to identify factors associated with mortality. Results We identified 142 patients who developed biliary complications: 83 of these patients had a successful endoscopic therapy, whereas 45 had a failure. Fourteen patients, who developed nonanastomotic biliary stricture, were excluded from the analysis. Patients with biliary complications who had pretransplant Model for End-Stage Liver Disease score more than 10 [odds ratio (OR) 3.88; 95% confidence interval (CI) 1.16–12.95; P=0.03] and stent retention time more than 12 months (OR 6.45; 95% CI 2.14–19.42; P<0.01) were less likely to respond to endoscopic therapy. In contrast, both dilatation and stenting procedures (OR 0.10; 95% CI 0.03–0.30; P<0.01) and 10 Fr diameter stent placement (OR 0.21; 95% CI 0.07–0.70; P=0.01) predicted favorable endoscopic treatment outcome. Time to the occurrence of biliary complications of more than 3 months [hazard ratio (HR) 0.24; 95% CI 0.10–0.56] and placement of five or more stents (HR 0.31; 95% CI 0.12–0.79) were found to be protective against mortality, whereas hepatic artery thrombosis was a significant risk factor for mortality (HR 13.88; 95% CI 4.08–47.25). Conclusion We found endoscopic treatment to be less effective in patients with pretransplant Model for End-Stage Liver Disease score more than 10 and stent retention time more than 12, whereas dilatation and stenting procedure and 10 Fr diameter stent placement predicted a favorable outcome.